Cargando…
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
More than 2000 immuno-oncology agents are being tested or are in use as a result of the cancer immunotherapy revolution. Manipulation of co-inhibitory receptors has achieved tumor eradication in a minority of patients, but widespread immune-related adverse events (irAEs) compromised tolerance to hea...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183506/ https://www.ncbi.nlm.nih.gov/pubmed/32152702 http://dx.doi.org/10.1007/s00262-020-02543-6 |